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Introduction {#sec001}
============

Inhaled antibiotics are important for the suppression of chronic *P*. *aeruginosa* (PA) infection in patients with cystic fibrosis (CF). Aztreonam lysine (AZLI, Cayston^®^) for inhalation solution was licensed in Europe in 2009 for the suppressive therapy of chronic pulmonary infections due to *Pseudomonas aeruginosa* in patients with CF aged 6 years and older. The pivotal clinical trials were conducted in patients with impaired lung function, i.e. forced expiratory volume in one second (FEV~1~) ≤75% of the predicted normal value\[[@pone.0221673.ref001]--[@pone.0221673.ref003]\]. In patients with moderate to severe lung disease, Aztreonam was superior to tobramycin inhalation.

Due to the improved general condition of current CF populations, many patients have normal or near normal FEV~1~ despite chronic *P*. *aeruginosa* infection \[[@pone.0221673.ref004]\]. Only little information is available about the efficacy of inhaled antipseudomonal antibiotics in these subjects. In general, with small patient cohorts of up to 20 patients, it is difficult to detect changes after treatment using FEV~1~ as an endpoint \[[@pone.0221673.ref005],[@pone.0221673.ref006]\]. This is particularly relevant if two active compounds are to be compared or if the inhaled antibiotic is switched from a conventional to a new drug. At the CF Centre Innsbruck, we have been using the multiple breath washout (MBW) technique for many years to measure lung clearance index (LCI) \[[@pone.0221673.ref007]\]. Abnormal LCI is associated with early structural lung disease detectable by high resolution computerized tomography (HRCT) scans when FEV~1~ may still be normal.

For the present feasibility study in subjects with mild lung disease, we hypothesised that LCI could better detect improvements after inhaled antibiotics than FEV~1~. When the study was designed, AZLI was not yet a standard treatment at our centre. At that time, patients with chronic *P*. *aeruginosa* infection inhaled either tobramycin or colistin on a long-term basis. We performed a pilot study comparing AZLI with standard inhaled antibiotics in a small group of patients with normal FEV~1~ (≥75% of the predicted normal value).

Methods {#sec002}
=======

This single-centre, observational, open-label, feasibility study compared two treatment phases, each consisting of 4-week on/off-cycles with inhaled antibiotics: Phase 1, weeks 0 to 8: standard inhaled antibiotic (tobramycin/TOBI^®^ 300mg/5ml BID or TOBI Podhaler^®^ 112mg BID), and Phase 2, weeks 8 to 16: AZLI 75 mg TID. ALZI was provided by Gilead Sciences, the manufacturer of AZLI. For each patient, the study started at the end of a 4-week off-period without standard inhaled antibiotic ("washout"). The patient recruitment period was from June 2014 to January 2016.

The main inclusion criteria were: clinically stable patients aged ≥12 years with CF, FEV~1~ ≥75% of the predicted normal value, chronic *P*. *aeruginosa* lung infection \[[@pone.0221673.ref008]\], and at least two previous on/off cycles or \> 8 weeks of continuous inhaled antibiotic treatment with tobramycin. Major exclusion criteria were age ≥ 50 years, acute upper or lower respiratory infections or pulmonary exacerbations.

The primary endpoint was lung clearance index (LCI) measured by nitrogen multiple breath washout using 100% oxygen (EasyOne Pro^®^ LAB MBW Module, ndd Medical Technologies, Zürich, Switzerland), with an upper limit of normal of 7.0 \[[@pone.0221673.ref009]\]. MBW testing and spirometry were performed before a session of standard physiotherapy. Secondary endpoints were prebronchodilator FEV~1~ using reference values from the global lung initiative (GLI) \[[@pone.0221673.ref010]\]. Respiratory symptoms were determined with the Cystic Fibrosis Questionnaire---Revised Respiratory Symptom scale \[[@pone.0221673.ref011]\]. Adverse events were documented at each study visit.

When we initially designed the study, we performed a sample size calculation. During our five years of experience with LCI measurements we had observed a LCI standard deviation of 1.25 in relatively healthy CF patients. For the present study, we assumed that LCI will improve after AZLI by at least the same magnitude as after hypertonic saline \[[@pone.0221673.ref012]\], probably more. Using these figures, a sample size of 10 had 80% power to detect a difference between means of 0.85 with a significance level (alpha) of 0.05 (two-tailed) in a paired t-test.

Data are expressed as median and range unless otherwise stated. For each parameter, the relative changes from start to end of the two treatment periods were determined. The non-parametric Wilcoxon signed rank test was used to compare the relative changes during AZLI and standard treatment phases. The study protocol ([S1 Protocol](#pone.0221673.s004){ref-type="supplementary-material"}) was approved by the Ethics committee of Medical University of Innsbruck (EC Number: UN 2013--0014_LEK Sitzungsnummer: 330/2.5), EudraCT Number: 2013-004295-35, there was no deviation from this study protocol ([S1 Protocol](#pone.0221673.s004){ref-type="supplementary-material"}). Written informed consent was obtained from all individual participants included in the study.

Results {#sec003}
=======

A total of 12 patients were approached, three patients had too little time to participate in the study due to heavy workload, and one subject did not meet inclusion criteria. Eight patients with CF aged 15 to 49 years (median 28 yrs.) participated in the trial ([Fig 1](#pone.0221673.g001){ref-type="fig"}). They had been chronically infected with *P*. *aeruginosa* for 6.5 years and had inhaled antipseudomonal antibiotics for 4.2 years. FEV~1~ ranged from 76.3 to 123.8% predicted (median 87.0%) and the FEV~1~ GLI z-score from -2.20 to 2.04 (median -1.24). Median body mass index was normal (21.5 kg/m^2^), and the median CFQ-R Respiratory symptom scale of 83.3 (range 78 to 94) showed only few limitations. Despite near normal spirometry, the median lung clearance index of 8.59 (range 6.4 to 11.4) was above the upper limit of normal (7.0), with only two patients showing normal values at the start of the study. The standard inhaled antibiotic was tobramycin in all subjects, with n = 5 subjects using TOBI Podhaler^®^ 112 mg BID and n = 3 inhaling TOBI^®^ 300 mg/5 ml nebuliser solution BID. Since previous authors had reported comparable safety and efficacy profiles of the two tobramycin treatments \[[@pone.0221673.ref013],[@pone.0221673.ref014]\], we analysed the combined results from both treatments.

![CONSORT participant flow diagram.](pone.0221673.g001){#pone.0221673.g001}

After 4 weeks of AZLI treatment, the primary endpoint LCI improved (i.e. declined) in 7 of 8 patients, while only 4 of 8 patients showed better results after tobramycin inhalation ([Fig 2](#pone.0221673.g002){ref-type="fig"}).

![LCI during and after inhalation with TOBI^®^ and AZLI.\
Decreasing values indicate improvement in lung function.](pone.0221673.g002){#pone.0221673.g002}

The treatment responses determined with LCI were more favourable after AZLI than after tobramycin (-0.365 vs. +0.120, p = 0.039, [Fig 3](#pone.0221673.g003){ref-type="fig"}).

![**Changes in LCI (left) or FEV**~**1**~ **z-score (right) after inhaled antibiotics.** More favourable LCI response to AZLI.](pone.0221673.g003){#pone.0221673.g003}

In contrast, no statistically significant differences between AZLI and standard treatment were observed with FEV~1~ as an endpoint (FEV~1~ z-score: +0.05 vs -0.15, p = 0.195; FEV~1~% predicted: +0.50 vs -1.80, p = 0.195), [S1](#pone.0221673.s002){ref-type="supplementary-material"} and [S2](#pone.0221673.s003){ref-type="supplementary-material"} Tables.

Respiratory symptoms showed clinically important improvements after AZLI treatment (median change +8.5) and better results (p = 0.031) than after tobramycin (median -3.0). Treatments were well tolerated, and no adverse events were reported.

Discussion {#sec004}
==========

In a small group of patients with cystic fibrosis and mild lung disease, greater improvements in lung clearance index and respiratory symptoms were observed after a 4-week course of AZLI compared to the standard inhaled antibiotic tobramycin. In contrast, FEV~1~ did not show significant differences between the two treatment periods. The results of this small feasibility study are in agreement with previous findings that using FEV~1~ as an outcome measure requires larger groups of patients with predominantly moderate to severe lung disease and a greater potential for improvement \[[@pone.0221673.ref015]--[@pone.0221673.ref018]\].

This is the first comparison of AZLI and tobramycin inhalation in patients with mild lung disease, as indicated by an FEV~1~ \> 75% of the predicted normal value. Superiority of AZLI over tobramycin has so far been reported only in patients with more advanced lung disease. After 4 weeks of AZLI inhalation, mean relative improvements of 8.4% from baseline FEV~1~% predicted were observed, while changes after tobramycin (+0.6% form baseline) were considerably smaller \[[@pone.0221673.ref019]\]. Several studies in relatively healthy patients with mild lung disease have compared AZLI with placebo. In 76 patients with mild lung disease, FEV~1~ improved significantly after AZLI only in patients with a baseline FEV~1~ of \< 90% predicted \[[@pone.0221673.ref020]\]. Also, the AZLI Phase 2 study showed no greater improvement in FEV~1~ after 14 days of AZLI treatment compared to placebo in the subset of 32 patients with FEV~1~ \> 75% predicted \[[@pone.0221673.ref001]\]. Thus, researchers were unable to show greater improvements in lung function after AZLI compared to tobramycin inhalation in mildly affected patients when FEV~1~ was used as the primary outcome parameter \[[@pone.0221673.ref020]\].

The study had several limitations. First, the patients cohort of this single-centre study was small compared to the international, multi-centre pivotal studies. Second, we were unable to recruit the desired number of 10 patients within a reasonable time. This limits the power of the study.

So far the minimal clinically important difference for LCI has not been defined \[[@pone.0221673.ref018]\]. Expert committees stated that LCI is a valuable potential outcome parameter in patients with normal FEV~1~, since LCI can detect treatment differences even in small patient groups \[[@pone.0221673.ref015],[@pone.0221673.ref017]\].

The results of this feasibility study are in line with the above statements and suggest that LCI should be considered as a clinical endpoint for trials in patients with early lung disease.
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